Friday, November 21, 2014 10:45:10 AM
This has never been an issue with KBLB's transgenic silkworm lines.
The problem seen by Randy Lewis (and perhaps others) is caused by a problem with earlier / cruder transgenic vehicles.
The transcriptase tended to remain active within the genome causing random mutations for several generations which had to be weeded out of each filial generation, but which such selection decreased over time.
One of the major improvements made by Malcolm Fraser with his (PiggyBAC) transposon was that such unwanted remnant activity was greatly reduced.
This was never an issue with the ZFN CompoZr agents as they use a different mechanism.
In any event, such genetic drift should be removed over the course of a dozen or so generations, many fewer than the Monster Worms(TM) have had, FOR THE TRANSGENIC PART OF THE GENOME where culling can be done on the basis of eye color or fluorescent pigments, so that the MS line is purely homozygotic with respect to the Spider Silk genes.
For the native parts of the genome there are no such markers, and the worms are not homozygotic as a whole (over the entire genome).
The latest testing and selection process announced by KBLB extends these selective breeding techniques to the genome as a whole (with respect to Silk production and consistency and strength).
This new process will / would improve the quality and consistency of ANY silkworm silk,not just MS.
Mike L.
Recent KBLB News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:31:54 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/16/2023 09:30:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:43:51 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/11/2023 08:30:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/08/2023 04:15:15 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/01/2023 08:30:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:35:05 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM